Plain-English translation of NCT06219018 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether L-Mesitran, a medical grade honey formulation, can help treat cervical intraepithelial neoplasia grade 2 (CIN II)—early abnormal changes in cervical cells caused by a high-risk virus. Women who prefer to watch and wait rather than have surgery are invited to apply this medication daily for three months, then weekly for another three months. Researchers will compare how well the medication works against a control group of women who don't use it.
Many women with early cervical cell changes prefer not to have surgery right away and instead choose careful monitoring. This study explores whether this medication might help the body clear these abnormal cells naturally, and researchers want to understand how it works at the cellular level.
You likely qualify if…
You likely don't qualify if…
You will apply the medical grade honey yourself using an applicator—5 grams daily for the first three months, then weekly for the next three months. You'll have check-up visits at six months and beyond, following standard cervical cancer screening guidelines. Researchers will also take vaginal swabs at the start and six-month mark to study how the treatment affects your vaginal bacteria, and they will examine cells from your cervix under a microscope to look for immune changes.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Netherlands
Phase
Safety & dosing / Early efficacy
Sponsor
Zuyderland Medisch Centrum
Enrollment target
~60 participants
Started
December 2024
Primary completion
December 2026
Age range
18 Years – 40 Years
Sex
Female only
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jordy Mongula, dr.
Zuyderland Medisch Centrum
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.